 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Key Insights The projected fair value for FibroGen is US$0.41 based on 2 Stage Free Cash Flow to Equity FibroGen's...

A Look At The Intrinsic Value Of FibroGen, Inc. (NASDAQ:FGEN)

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript...

FibroGen, Inc. (FGEN) Q3 2023 Earnings Call Transcript

FibroGen, Inc. 2023 Q3 - Results - Earnings Call Presentation...

FibroGen, Inc. 2023 Q3 - Results - Earnings Call Presentation

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

FibroGen reports Q3 EPS (65c), consensus (68c)

Topline data from two pivotal pamrevlumab pancreatic cancer trials on track to read out in 1H 2024, including the Pancreatic Cancer Action Network (PanCAN) Precision PromiseSM Phase 2/3 study in...

FibroGen Reports Third Quarter 2023 Financial Results

SAN FRANCISCO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its third quarter 2023 financial results on Monday, November 6 after the market close. FibroGen will...

FibroGen to Report Third Quarter 2023 Financial Results

Investors eyeing a purchase of FibroGen Inc (FGEN) shares, but cautious about paying the going market price of 0.9626/share, might benefit from considering selling puts among the alternative...

#36;0.50, Earn 10% Using Options

In trading on Wednesday, drugs shares were relative leaders, up on the day by about 2.6%. Leading the group were shares of ADC Therapeutics, up about 681.2% and shares of FibroGen up about 14.5% on...

Video: Wednesday Sector Leaders: Drugs, Precious Metals

Study did not meet the primary endpoint Pamrevlumab was generally safe and well tolerated SAN FRANCISCO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced...

FibroGen Announces Topline Results from LELANTOS-2, a Phase 3 Clinical Study of Pamrevlumab in Ambulatory Duchenne Muscular Dystrophy

BofA downgrades FibroGen to underperform, cites unfavorable catalysts

FibroGen, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993 and is headquartered in San Francisco, CA.

Watchers	4,023
52-Wk Low	$0.3333
52-Wk High	$25.69

Market Cap	$61.8M
Volume (M)	2.1M
52-Wk High	$25.69
52-Wk Low	$0.3333

FGEN FibroGen Inc

About

Feed

News

Sentiment

Earnings

Fundamentals